Chris Ryan

The biologics license application for subcutaneous amivantamab is seeking approval for the treatment of EGFR-positive non-small cell lung cancer.

The FDA approved durvalumab plus carboplatin and paclitaxel, followed by single-agent durvalumab for primary advanced or recurrent dMMR endometrial cancer.

Findings from a retrospective study may shed light on the prognostic value of PD-L1 expression in metastatic papillary renal cell carcinoma.

The priority review granted by the FDA to the supplemental new drug application for osimertinib is seeking approval for its treatment of stage III non-small cell lung cancer with EGFR mutations.

Rates of MRD negativity increased with daratumumab plus VRd in newly diagnosed, transplant-eligible multiple myeloma.

Patients with HR-positive, HER2-low, and -ultralow metastatic breast cancer treated with trastuzumab deruxtecan obtained a PFS benefit vs chemotherapy.

Compared with placebo, osimertinib after definitive chemoradiotherapy improved progression-free survival in locally advanced, EGFR-mutated non–small cell lung cancer.

A breakthrough device designation has been granted by the FDA to Teal Wand, an at-home screening test for cervical cancer.

HPV vaccines in patients under the age of 40 may have lowered rates of HPV-related cancer compared with unvaccinated patients.

The accelerated approval of infigratinib has been withdrawn by the FDA for previously treated, FGFR2-positive, advanced cholangiocarcinoma.

Frontline treatment with pembrolizumab plus trastuzumab/chemotherapy significantly and meaningfully improved overall survival in HER2-positive, unresectable or metastatic gastric/GEJ cancer.

Glecirasib resulted in durable responses with a manageable safety profile for pretreated advanced non-small cell lung cancer with KRAS G12C mutations.

A screening test has been approved by the FDA for adults 45 years of age or older with an average risk for developing colorectal cancer.

Trastuzumab deruxtecan enhanced survival without disease progression compared with chemotherapy in HR-positive, HER2-low metastatic breast cancer after 1 or more lines of endocrine therapy.

The optical imaging agent Lumisight and the Lumicell Direct Visualization System received approval from the FDA for fluorescence imaging in breast cancer.

The biologics license application for datopotamab deruxtecan has been accepted by the FDA for pretreated HR-positive, HER2-negative metastatic breast cancer.

The preference of subcutaneous atezolizumab compared with its intravenous formulation was demonstrated in patients with non–small cell lung cancer treated on the IMscin002 trial.

The new drug application for revumenib is supported by data from the AUGMENT-101 trial of patients with KMT2A-rearranged acute myeloid leukemia or acute lymphoblastic leukemia.

The benefits noted in this exploratory analysis were irrespective of the number of neoadjuvant treatment cycles completed in patients with resectable non-small cell lung cancer.

The safety label for fluorouracil products will now include information about the agent’s use in patients with dihydropyrimidine dehydrogenase deficiency.

An expert discusses how radiation may improve quality of life in patients with rectal cancer, in addition to when radiation or surgery could be omitted.

The Oncologic Drugs Advisory Committee of the FDA unanimously voted in favor of ciltacabtagene autoleucel for the treatment of early relapsed/refractory myeloma.

Compared with placebo, first-line niraparib maintenance was not linked with worsened health-related quality of life outcomes in patients with advanced ovarian cancer.

The FDA granted an orphan drug designation to avutometinib either alone or in combination with defactinib for recurrent low-grade serous ovarian cancer.

Patients with unresectable or metastatic melanoma treated with the universal cancer vaccine UV1 plus nivolumab and ipilimumab did not experience an improvement in progression-free survival vs nivolumab plus ipilimumab alone.

Patients with FIGO stage IV ovarian cancer did not experience additional complications or worse survival with HIPEC compared with those with stage III disease.

The PD-L1 IHC 22C3 pharmDx diagnostic tool will help identify patients with gastric or gastroesophageal junction adenocarcinoma whose disease expresses PD-L1 and who are thereby eligible for pembrolizumab.

Adjuvant pembrolizumab improved overall survival vs placebo in patients with renal cell carcinoma at intermediate-high or high risk of recurrence.

Patients who received induction chemotherapy prior to chemoradiation had a 35% reduced risk of progression or death.

The FDA has approved tests to identify patients with metastatic non–small cell lung cancer who are eligible for treatment with encorafenib plus binimetinib.